Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Dalantercept"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Textbook of Vascular Medicine ISBN: 9783030164805
The transforming growth factor (TGF)-β superfamily includes 32 cytokines that tightly regulate vascular cell behaviour such as proliferation, migration, apoptosis, differentiation and extracellular matrix (ECM) maintenance, production and remodellin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b567348916890deba75a059cda626fef
https://doi.org/10.1007/978-3-030-16481-2_13
https://doi.org/10.1007/978-3-030-16481-2_13
Publikováno v:
Biochemical Society Transactions. 44:1135-1141
Bone morphogenetic protein (BMP)9 and BMP10 are high affinity ligands for activin receptor-like kinase 1 (ALK1), a type I BMP receptor mainly expressed on vascular endothelial cells (ECs). ALK1-mediated BMP9/BMP10 signalling pathways have emerged as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff43c0660e851ee31237d0e521507e1e
https://doi.org/10.1042/bst20160083
https://doi.org/10.1042/bst20160083
Autor:
Vicky Makker, Virginia L. Filiaci, Katherine M. Moxley, Carol Aghajanian, Christopher J. Darus, Gregory P. Sutton, Lee-may Chen, James E. Kendrick
Publikováno v:
Gynecologic oncology, vol 138, iss 1
Objective This two-stage phase II study assessed activity of single agent dalantercept in patients with recurrent/persistent endometrial carcinoma (EMC). Methods Eligible patients had persistent/recurrent EMC after 1–2 prior cytotoxic regimens, mea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b48e8e4f0fe6717fa7104ecbd0fdbde2
https://doi.org/10.1016/j.ygyno.2015.04.006
https://doi.org/10.1016/j.ygyno.2015.04.006
Autor:
Marat Alimzhanov, Sabina Signoretti, David C. Alsop, Manoj Bhasin, Jiaxi Song, James W. Mier, Rupal S. Bhatt, Xiaoen Wang, Michael B. Atkins, Nicolas Solban, R. Scott Pearsall, Marcella Callea, Ravi Kumar, Prateek Khanna
Publikováno v:
Oncotarget
Treatment of metastatic renal cell carcinoma (mRCC) with agents that block signaling through vascular endothelial growth factor receptor 2 (VEGFR2) induces disease regression or stabilization in some patients; however, these responses tend to be shor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e7b328332d812bd22d2bdda7d061573
https://pubmed.ncbi.nlm.nih.gov/27248821
https://pubmed.ncbi.nlm.nih.gov/27248821
Publikováno v:
Biochemical Society Transactions; 44(4), pp 1142-1149 (2016)
Biochemical Society Transactions, 44, 1142-1149
Biochemical Society Transactions, 44, 1142-1149
Angiogenesis is a hallmark of cancer and is now a validated therapeutic target in the clinical setting. Despite the initial success, anti-angiogenic compounds impinging on the vascular endothelial growth factor (VEGF) pathway display limited survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66bf5a93af326792d2f86b1d3935093b
https://hdl.handle.net/1887/113833
https://hdl.handle.net/1887/113833
Publikováno v:
Current Oncology Reports. 17
Development of anti-angiogenic therapy including the vascular endothelial growth factor (VEGF) antibodies and VEGF-tyrosine kinase receptors has been a major landmark in cancer therapy leading improvement in survival in several cancers. While anti-an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d9e3d17fd38de59673009d6cf651c25
https://doi.org/10.1007/s11912-015-0441-5
https://doi.org/10.1007/s11912-015-0441-5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
George Philips, Michael B. Atkins
Publikováno v:
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
The vascular endothelial growth factor (VEGF) pathway blockers and mammalian target of rapamycin (mTOR) inhibitors have dramatically improved the treatment options and outcome for patients with advanced renal cell carcinoma (RCC). However, because th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aeeb7eba89a5c2e4a9a9ae57184fc1b2
https://pubmed.ncbi.nlm.nih.gov/24857106
https://pubmed.ncbi.nlm.nih.gov/24857106
Autor:
Vicky Makker, Douglas A. Levine, James L. Wade, Heidi J. Gray, Heather A. Lankes, Carol Aghajanian, Robert A. Burger, Steven E Waggoner, Wei Deng
Publikováno v:
Journal of Clinical Oncology. 34:e17050-e17050
e17050Background: Activin receptor-like kinase 1 (ALK1) drives the maturation phase of angiogenesis. We conducted a two-stage, phase II trial of dalantercept, a soluble ALK1 inhibitor receptor fusi...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2957f55124b89356b0ba93c62d03d2aa
https://doi.org/10.1200/jco.2016.34.15_suppl.e17050
https://doi.org/10.1200/jco.2016.34.15_suppl.e17050